MaltSci 麦伴科研

Appearance

Popular Reports / Emerging Frontiers

This report is written by MaltSci based on the latest literature and research findings

What are the applications of organoids? ​

Abstract ​

Organoids, three-dimensional (3D) structures derived from stem cells, have emerged as transformative tools in biomedical research, mimicking the architecture and functionality of real organs. This innovative technology allows for a more physiologically relevant model compared to traditional two-dimensional (2D) cell cultures, thereby facilitating a deeper understanding of organ development, disease mechanisms, and drug responses. The increasing complexity of diseases, alongside the limitations of conventional research methodologies, underscores the necessity for advanced models that can accurately reflect human biology. Organoids have become pivotal in various domains, including regenerative medicine, cancer research, and personalized medicine. They provide an invaluable platform for studying the intricate interactions between different cell types within an organ, enabling researchers to investigate disease pathogenesis and therapeutic responses in a controlled environment. Furthermore, organoids derived from patient tissues offer a unique opportunity for personalized medicine, allowing for the tailoring of treatments based on individual genetic and phenotypic characteristics. Recent advancements in organoid technology, including improvements in engineering methods and integration with cutting-edge techniques such as microfluidics and gene editing, have further enhanced their applicability in drug discovery and regenerative therapies. Despite the promising potential of organoids, the field faces several challenges. Technical limitations, such as the difficulty in replicating the complex microenvironment of human organs and achieving consistent vascularization, pose significant hurdles. Additionally, ethical considerations surrounding the use of stem cells and the transition from research to clinical applications necessitate careful navigation. Addressing these challenges will be crucial for the successful integration of organoid technology into routine clinical practice. In summary, organoids represent a revolutionary advancement in biomedical research, offering new avenues for understanding complex biological systems and improving clinical outcomes. As research continues to evolve, the integration of organoid technology into mainstream medicine holds the promise of enhancing personalized treatment strategies and ultimately transforming patient care.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Organoid Technology: An Overview
    • 2.1 Definition and Types of Organoids
    • 2.2 Methods of Organoid Generation
  • 3 Applications of Organoids in Disease Modeling
    • 3.1 Cancer Research
    • 3.2 Genetic Disorders
    • 3.3 Infectious Diseases
  • 4 Organoids in Drug Discovery and Development
    • 4.1 High-Throughput Screening
    • 4.2 Personalized Medicine Approaches
  • 5 Therapeutic Applications of Organoids
    • 5.1 Regenerative Medicine
    • 5.2 Organoid Transplants
  • 6 Challenges and Future Directions
    • 6.1 Technical Limitations
    • 6.2 Ethical Considerations
  • 7 Conclusion

1 Introduction ​

Organoids, three-dimensional (3D) structures derived from stem cells, have emerged as transformative tools in biomedical research, mimicking the architecture and functionality of real organs. This innovative technology allows for a more physiologically relevant model compared to traditional two-dimensional (2D) cell cultures, thereby facilitating a deeper understanding of organ development, disease mechanisms, and drug responses. The increasing complexity of diseases, alongside the limitations of conventional research methodologies, underscores the necessity for advanced models that can accurately reflect human biology. As such, organoids have become pivotal in various domains, including regenerative medicine, cancer research, and personalized medicine, heralding a new era in biomedical applications [1][2].

The significance of organoids in research cannot be overstated. They provide an invaluable platform for studying the intricate interactions between different cell types within an organ, enabling researchers to investigate disease pathogenesis and therapeutic responses in a controlled environment. Furthermore, organoids derived from patient tissues offer a unique opportunity for personalized medicine, allowing for the tailoring of treatments based on individual genetic and phenotypic characteristics [3][4]. Recent advancements in organoid technology, including improvements in engineering methods and integration with cutting-edge techniques such as microfluidics and gene editing, have further enhanced their applicability in drug discovery and regenerative therapies [5][6].

Despite the promising potential of organoids, the field faces several challenges. Technical limitations, such as the difficulty in replicating the complex microenvironment of human organs and achieving consistent vascularization, pose significant hurdles. Additionally, ethical considerations surrounding the use of stem cells and the transition from research to clinical applications necessitate careful navigation [7][8]. Addressing these challenges will be crucial for the successful integration of organoid technology into routine clinical practice.

This report is structured to provide a comprehensive overview of the current applications of organoids, organized as follows: First, we will explore the foundational aspects of organoid technology, including definitions, types, and methods of generation. Next, we will delve into the applications of organoids in disease modeling, highlighting their roles in cancer research, genetic disorders, and infectious diseases. Following this, we will discuss the utility of organoids in drug discovery and development, focusing on high-throughput screening and personalized medicine approaches. We will then examine therapeutic applications, particularly in regenerative medicine and organoid transplants. Finally, we will address the challenges and future directions in the field, emphasizing the need for interdisciplinary innovation to fully harness the potential of organoids in biomedicine [9][10].

In summary, organoids represent a revolutionary advancement in biomedical research, offering new avenues for understanding complex biological systems and improving clinical outcomes. As research continues to evolve, the integration of organoid technology into mainstream medicine holds the promise of enhancing personalized treatment strategies and ultimately transforming patient care [11][12].

2 Organoid Technology: An Overview ​

2.1 Definition and Types of Organoids ​

Organoids are three-dimensional (3D) cell culture systems derived from human pluripotent or adult stem cells that closely mimic the structure and function of human organs. They have emerged as invaluable tools in various fields of biomedical research due to their ability to replicate the complexity of native tissues while retaining human genetic material. The applications of organoids are diverse and include disease modeling, drug discovery, regenerative medicine, and personalized medicine.

In disease modeling, organoids provide a platform for studying the mechanisms of various diseases, including cancer, infectious diseases, and genetic disorders. They allow researchers to investigate disease progression and response to treatments in a controlled environment. For instance, patient-derived organoids have been particularly useful in cancer research, enabling the evaluation of drug sensitivity and informing personalized treatment plans. In colorectal cancer, organoids derived from tumor tissues allow for drug sensitivity tests, demonstrating their potential to guide individualized therapy [4].

Organoids also play a crucial role in drug discovery and development. They serve as models for high-throughput drug screening, allowing researchers to assess drug efficacy and toxicity more accurately than traditional two-dimensional (2D) cell cultures. The use of organoids can significantly shorten the drug development timeline and reduce the reliance on animal models, aligning with ethical considerations in biomedical research [7]. Additionally, organoids are utilized to study drug interactions and mechanisms of action, contributing to the advancement of pharmacological research [2].

In regenerative medicine, organoids hold promise for tissue engineering and repair. They can be used to generate tissues for transplantation or to study tissue regeneration processes. For example, organoids have been explored for their potential in regenerating damaged tissues in the liver, intestine, and other organs [8]. Furthermore, engineered organoids are being developed to enhance their functionality and integration into host tissues, which is critical for their application in clinical settings [13].

Personalized medicine is another significant application of organoids. By generating organoids from individual patients, researchers can create biobanks that facilitate the development of tailored therapeutic strategies. This approach enables the testing of specific treatments on patient-derived organoids, thereby improving the chances of successful outcomes in clinical settings [14].

Organoids are also utilized in studying interactions between different cell types within the microenvironment, such as immune responses in tumor organoids, which is essential for advancing immunotherapy [15]. Moreover, advancements in organoid technology, including the integration of artificial intelligence and microfluidics, are enhancing their applications across various domains, including biomaterial toxicity analysis and the modeling of complex diseases [16].

In summary, organoids are a transformative technology in biomedical research, with applications spanning disease modeling, drug discovery, regenerative medicine, and personalized medicine. Their ability to replicate human organ physiology and disease states makes them indispensable tools for advancing our understanding of human biology and improving therapeutic strategies.

2.2 Methods of Organoid Generation ​

Organoids, as three-dimensional (3D) cellular structures derived from pluripotent or adult stem cells, have emerged as powerful tools in various biomedical applications. They replicate the architecture and functionality of human organs, providing significant advantages in research and clinical settings. The applications of organoids can be broadly categorized into several domains, including disease modeling, drug discovery, regenerative medicine, and personalized medicine.

In disease modeling, organoids are utilized to closely mimic the cellular environment and disease processes of specific organs. For instance, patient-derived organoids have been developed for cancer research, allowing for the study of tumor behavior, drug sensitivity, and the efficacy of various treatment regimens. This approach has been particularly effective in cancers such as colorectal cancer, where organoids derived from tumor tissues enable tailored therapeutic strategies based on individual patient responses [4]. Furthermore, organoids have been instrumental in modeling infectious diseases and genetic disorders, thereby enhancing our understanding of disease mechanisms and progression [3].

In the realm of drug discovery, organoids provide a more accurate platform for assessing drug efficacy and safety compared to traditional two-dimensional cell cultures. They facilitate high-throughput screening of compounds, allowing researchers to evaluate the pharmacological effects of new drugs in a system that closely resembles human physiology [2]. The integration of organoids with advanced technologies such as artificial intelligence and microfluidics further enhances their utility in drug testing and development [5].

Regenerative medicine is another significant application of organoids. They hold potential for tissue engineering and the development of transplantable tissues. For example, organoids can be engineered to repair damaged tissues or regenerate specific organ functions, providing a promising avenue for treating degenerative diseases and injuries [13]. The ability to manipulate organoids genetically using technologies like CRISPR-Cas9 also opens new pathways for developing personalized therapies [14].

Personalized medicine is increasingly leveraging organoid technology, as biobanks of patient-derived organoids can inform tailored treatment plans. This approach not only enhances the precision of therapeutic interventions but also aligns with ethical considerations by reducing reliance on animal testing in drug development [4].

Moreover, organoids are being explored in the context of immunology, where they can model the interactions between immune cells and tumor microenvironments, aiding in the development of immunotherapies [17]. Their ability to replicate organ-specific functions makes them invaluable in understanding complex physiological processes and disease states.

In summary, organoids represent a versatile platform with applications spanning disease modeling, drug discovery, regenerative medicine, and personalized therapies. Their development continues to evolve, driven by advancements in engineering, genetic manipulation, and interdisciplinary approaches that aim to enhance their clinical utility and effectiveness in biomedical research [1][2][3].

3 Applications of Organoids in Disease Modeling ​

3.1 Cancer Research ​

Organoids, which are three-dimensional cultures derived from pluripotent or adult stem cells, have emerged as transformative tools in cancer research due to their ability to accurately mimic human organ architecture and function. Their applications in disease modeling, particularly in cancer research, are extensive and multifaceted.

One of the primary applications of organoids is in personalized medicine. Patient-derived organoids can be developed from tumor tissues, allowing researchers to perform drug sensitivity tests that inform tailored treatment plans. For instance, organoids from colorectal cancer patients have demonstrated their utility in evaluating responses to specific chemotherapy drugs, thereby facilitating personalized therapeutic strategies [4]. This ability to recapitulate patient-specific genomic and phenotypic characteristics makes organoids a powerful platform for individualized treatment approaches [18].

In addition to personalized therapy, organoids serve as valuable preclinical models for drug discovery and development. They provide a reliable technology platform for screening new drugs and assessing their efficacy and toxicity. For example, organoids have been utilized to test poly-ADP ribose polymerase (PARP) inhibitors, aligning with regulatory shifts aimed at reducing animal testing in drug development [4]. The versatility of organoids extends to their application in regenerative medicine, where they are being explored for tissue engineering and organ regeneration [4].

Organoids also play a critical role in understanding the mechanisms underlying cancer biology. They can be established from various stages of tumor evolution, enabling researchers to study tumor heterogeneity, growth, and metastasis with high fidelity. By recapitulating the tissue architecture and cellular diversity of human cancers, organoids allow for more accurate predictions of drug responses and tumor behavior [19]. Furthermore, they facilitate investigations into tumor-immune cell interactions, aiding in the design and testing of immune-based therapies and vaccines [19].

Recent advancements in organoid technology have further enhanced their applicability in cancer research. Innovations such as microfluidics, genetic editing, and bioprinting have improved the functional maturation and scalability of organoids, thus broadening their potential for applications in precision oncology [1]. Moreover, organoids can simulate the tumor microenvironment, providing insights into the complex interactions between cancer cells and their surroundings [1].

Despite their advantages, organoids face challenges such as variable culture conditions, limited vascularization, and high costs. However, ongoing efforts to standardize protocols and integrate microenvironmental factors are expected to enhance their clinical utility and drive further advancements in therapeutic development [4].

In summary, organoids represent a revolutionary advancement in cancer research, offering promising applications in personalized medicine, drug discovery, and the elucidation of cancer biology. Their ability to accurately model human tumors and their microenvironments positions them as invaluable tools in the quest for effective cancer therapies and better understanding of disease mechanisms.

3.2 Genetic Disorders ​

Organoids have emerged as pivotal tools in the field of biomedical research, particularly in the modeling of genetic disorders. Their ability to closely mimic the architecture and function of human organs makes them invaluable for understanding disease mechanisms, identifying novel pathogenic genes, and developing therapeutic strategies. The applications of organoids in the context of genetic disorders can be summarized as follows:

  1. Disease Modeling: Organoids provide a platform for modeling various genetic disorders by recapitulating the physiological and pathological features of the respective organs. This is particularly relevant for disorders with well-defined inheritance patterns, such as monogenic disorders, copy number variations (CNVs), and aneuploidies. They allow researchers to study the progression of these diseases in a controlled environment, facilitating insights into their underlying mechanisms (Zhu et al., 2025) [20].

  2. Identification of Pathogenic Genes: The use of organoid models has been instrumental in elucidating the genetic basis of diseases. By utilizing patient-derived organoids, researchers can directly assess the impact of specific genetic mutations on organ development and function, thereby identifying novel pathogenic genes associated with various genetic disorders (Yao et al., 2024) [5].

  3. Therapeutic Strategies: Organoids are being employed in the development of innovative therapeutic strategies, including drug screening platforms and gene-editing therapies. They allow for the evaluation of drug efficacy and toxicity in a human-relevant context, which is crucial for personalized medicine. For instance, organoids derived from patients with specific genetic disorders can be used to test targeted therapies, thus tailoring treatments to individual genetic profiles (Li et al., 2020) [14].

  4. Regenerative Medicine: Beyond modeling and drug testing, organoids hold promise in regenerative medicine. Their capacity to self-organize and maintain genetic fidelity enables the exploration of regenerative therapies for genetic disorders, potentially leading to breakthroughs in treatment options for patients suffering from these conditions (Banerjee & Senapati, 2024) [21].

  5. Multi-Omics Integration: The integration of organoid technology with multi-omics approaches (such as genomics, transcriptomics, and proteomics) enhances the understanding of genetic disorders at a systems level. This holistic view can uncover complex interactions between genes and pathways, providing deeper insights into the etiology of diseases (Huang et al., 2025) [1].

  6. Challenges and Future Directions: Despite the significant advancements in organoid technology, challenges remain, including the need to better recapitulate complex pathologies and the scalability of organoid production. Addressing these limitations is essential for maximizing the potential of organoids in personalized medicine and ensuring their effective application in clinical settings (Dutta et al., 2017) [22].

In summary, organoids represent a transformative approach in the study and treatment of genetic disorders, offering a bridge between basic research and clinical applications. Their capacity to model human diseases with high fidelity, combined with advancements in genetic engineering and multi-omics technologies, positions them at the forefront of precision medicine and therapeutic innovation.

3.3 Infectious Diseases ​

Organoids have emerged as a transformative tool in the study of infectious diseases, providing a more physiologically relevant model compared to traditional two-dimensional cell cultures and animal models. Their applications span various aspects of infectious disease research, including modeling host-pathogen interactions, drug screening, and vaccine development.

One significant application of organoids is in the modeling of viral infections. Organoids derived from human tissues, such as lung, liver, and intestinal organoids, closely mimic the architecture and function of the respective organs, allowing researchers to study systemic viral infections like SARS-CoV-2, Zika virus, and influenza virus, as well as localized infections caused by viruses such as respiratory syncytial virus and cytomegalovirus [23]. This modeling capability facilitates a better understanding of viral pathogenesis and the dynamics of host-virus interactions.

In the context of drug screening, organoids provide a platform to evaluate the efficacy and safety of antiviral drugs. Their three-dimensional structure allows for a more accurate assessment of drug responses in a microenvironment that closely resembles in vivo conditions. Recent studies have highlighted the potential of organoids to serve as reliable platforms for identifying effective antiviral agents, which is crucial for rapid responses to emerging infectious diseases [24].

Furthermore, organoids are instrumental in vaccine development. By enabling researchers to study the immune responses elicited by viral infections and the subsequent responses to vaccines, organoids can help identify the mechanisms of action and optimize vaccine formulations [25]. This application is particularly relevant in the face of recent global pandemics, where rapid vaccine development is essential.

The versatility of organoids extends to modeling interactions with various pathogens, including bacteria and protozoa. Their ability to replicate the tissue architecture and cellular interactions found in human organs allows for the investigation of complex host-pathogen dynamics that are often overlooked in simpler models [26]. This capability is critical for understanding the pathogenesis of infectious diseases and for the development of targeted therapies.

In addition to their use in basic research, organoids hold promise for personalized medicine. Patient-derived organoids can be utilized to assess individual responses to infections and treatments, paving the way for tailored therapeutic strategies [10]. This personalized approach can significantly enhance the effectiveness of interventions for infectious diseases, as treatments can be customized based on the specific characteristics of a patient's disease.

In summary, organoids represent a powerful and versatile tool in the study of infectious diseases, offering applications in modeling viral and bacterial infections, drug screening, vaccine development, and personalized medicine. Their ability to mimic human physiology and pathology closely positions them as a crucial resource in advancing our understanding and treatment of infectious diseases [27][28][29].

4 Organoids in Drug Discovery and Development ​

4.1 High-Throughput Screening ​

Organoids, as three-dimensional (3D) cellular models derived from stem cells, have significantly advanced drug discovery and development, particularly in the context of high-throughput screening (HTS). Their applications span various domains, including disease modeling, drug efficacy testing, and personalized medicine, providing a more accurate representation of human physiology compared to traditional two-dimensional (2D) cell cultures.

One of the primary advantages of organoids is their ability to closely mimic the complex architecture and functional characteristics of human tissues. This resemblance enables researchers to model diseases more effectively and assess drug responses in a way that is more relevant to human health. For instance, organoids derived from patient material can be utilized to evaluate individual drug responses, allowing for a tailored approach to therapy [30].

High-throughput screening with organoids offers several benefits. The integration of advanced technologies such as artificial intelligence (AI), machine learning, and automated liquid handling systems enhances the efficiency and scalability of drug testing. For example, the development of an automated platform for kidney organoids allows for the differentiation and phenotyping processes to be conducted entirely by liquid-handling robots, facilitating large-scale screening of drug candidates [31]. Additionally, high-content imaging techniques enable the quantification of drug effects on organoid morphology, providing critical insights into drug efficacy and safety [32].

Moreover, organoids are being increasingly employed in the screening of therapies for various diseases, including neurological disorders and cancers. Their ability to replicate tumor histopathology and cellular heterogeneity makes them particularly valuable in oncology, where they can predict therapeutic responses and inform clinical decisions [33]. Studies have demonstrated that patient-derived organoids can accurately reflect drug responses, leading to better outcomes in clinical settings [34].

Despite these advancements, challenges remain in the scalability and reproducibility of organoid cultures for high-throughput applications. Variability in organoid biology and the need for standardized protocols are ongoing concerns that researchers are actively addressing. For instance, the integration of biomaterials and microfluidics is being explored to enhance organoid stability and functionality, thereby improving their reliability in drug screening [35].

In summary, organoids represent a transformative approach in drug discovery and development, particularly in high-throughput screening. Their capacity to model human diseases accurately and predict drug responses positions them as essential tools in the quest for more effective and personalized therapies, ultimately enhancing the efficiency of the drug development process [36][37].

4.2 Personalized Medicine Approaches ​

Organoids have emerged as a revolutionary technology in the fields of drug discovery and personalized medicine, providing a more accurate representation of human tissues compared to traditional 2D cell cultures or animal models. These three-dimensional (3D) culture systems, derived from stem cells, recapitulate the cellular architecture and functionality of native organs, enabling a range of applications across biomedical research.

In drug discovery, organoids serve as powerful platforms for modeling diseases and assessing drug efficacy and toxicity. They allow researchers to evaluate drug responses in a more physiologically relevant context, thus enhancing the predictive power of preclinical studies. For instance, patient-derived organoids can be utilized to test the efficacy of various therapeutic agents on individual tumors, providing insights into personalized treatment strategies. This is particularly significant in oncology, where organoids derived from cancer patients can reveal the heterogeneity of tumors and the differential responses to therapies, thereby facilitating the selection of the most effective treatment for each patient (Singh et al. 2025; Yang et al. 2021) [36][38].

Furthermore, organoids play a crucial role in precision medicine approaches. By utilizing organoids generated from patient-specific tissues, clinicians can simulate disease processes and test drug responses tailored to the individual’s unique genetic makeup. This capability is enhanced by recent advancements in gene editing technologies such as CRISPR-Cas9, which allow for precise modeling of genetic disorders within organoids. Such innovations enable the integration of multi-omics data (transcriptomics, proteomics, and metabolomics) to provide comprehensive insights into drug metabolism and toxicity, thereby informing personalized therapeutic interventions (Yao et al. 2024; Huang et al. 2025) [1][5].

Additionally, the development of organoids-on-a-chip technology represents a significant advancement in personalized medicine. This approach combines organoid culture with microfluidic systems, enabling real-time drug testing and the simulation of organ interactions. This integration not only enhances the precision of drug screening but also facilitates the optimization of treatment strategies based on individual patient responses (Man et al. 2024) [39].

In summary, organoids are transforming drug discovery and personalized medicine by providing human-relevant models that closely mimic the complexities of native tissues. Their applications extend from disease modeling and drug testing to the development of tailored therapeutic strategies, thus holding great promise for advancing precision medicine and improving patient outcomes.

5 Therapeutic Applications of Organoids ​

5.1 Regenerative Medicine ​

Organoids, which are three-dimensional cultures derived from pluripotent or adult stem cells, exhibit remarkable potential in regenerative medicine due to their ability to mimic human organ architecture and function. Their applications in this field are diverse and significant, offering innovative strategies for tissue repair and regeneration.

One of the primary applications of organoids in regenerative medicine is their use as models for studying various diseases and testing potential therapeutic approaches. For instance, organoids derived from patient tissues can be employed to investigate the mechanisms of disease, allowing for the identification of novel therapeutic targets and the evaluation of drug efficacy in a patient-specific context. This personalized approach is particularly evident in the development of colorectal cancer organoids, where tumor tissues are utilized to perform drug sensitivity tests, thereby informing tailored treatment plans[4].

Furthermore, organoids have shown promise in regenerative applications beyond cancer treatment. They have been effectively used to explore regenerative mechanisms, such as the repair of intestinal stem cells following radiation exposure[4]. This capability extends to various organ systems, including the heart, liver, and kidney, where organoid technology is being developed to create transplantable tissues that can repair or replace damaged organs[40][41].

The integration of organoids with tissue engineering technologies has further enhanced their potential in regenerative medicine. Scholars are combining organoid cultures with advanced biomaterials to improve reproducibility and accuracy in tissue construction. This approach aims to create organoids that not only replicate the structural and functional characteristics of native tissues but also exhibit enhanced functionality and viability when transplanted[42][43].

Moreover, organoids are increasingly recognized for their role in addressing the challenges associated with traditional transplantation therapies, such as immunosuppression and sample availability. By utilizing stem cell-derived organoids, researchers are exploring new avenues for developing personalized therapies that circumvent these issues[44].

Despite their promising applications, the field of organoid-based regenerative medicine faces several challenges. Issues such as variable culture conditions, limited vascularization, and high costs need to be addressed to enhance the clinical utility of organoids. Standardizing protocols and incorporating microenvironmental factors are critical steps toward overcoming these hurdles and facilitating the transition of organoids from research settings to clinical applications[4][5].

In conclusion, organoids represent a revolutionary tool in regenerative medicine, with applications ranging from disease modeling and drug testing to the development of transplantable tissues. Their ability to closely mimic human physiology positions them as pivotal in advancing therapeutic strategies aimed at repairing and regenerating damaged organs. Continued research and innovation in this field are essential for realizing the full potential of organoids in clinical settings.

5.2 Organoid Transplants ​

Organoids have emerged as powerful tools in regenerative medicine, particularly in the context of organoid transplants. Their three-dimensional structure and ability to mimic the architecture and function of native tissues provide a unique platform for therapeutic applications, including tissue repair and transplantation.

One of the significant advantages of organoids is their potential to overcome the limitations associated with traditional transplantation methods. Conventional therapies often rely on heterologous transplantation, which can be hindered by issues such as sample availability, ethical concerns, and the need for immunosuppressive medications to prevent rejection. In contrast, organoids can be derived from a patient’s own cells, reducing the risk of immune rejection and allowing for personalized therapy. This aspect is particularly beneficial for conditions where tissue damage is prevalent, such as in regenerative medicine applications [44].

The engineering of organoids has further enhanced their applicability in transplantation. Recent advancements in bioengineering have focused on improving the reproducibility, accuracy, and throughput of organoid cultivation. Techniques such as genetic correction and the integration of organoids with tissue engineering strategies are being explored to create more functional and viable transplantable tissues [13]. These engineered organoids hold the promise of addressing challenges such as vascularization and functionality that have traditionally limited the success of organoid transplants [45].

In addition to their use in regenerative medicine, organoids are instrumental in modeling diseases and evaluating therapeutic responses. They provide a platform for studying the underlying mechanisms of various conditions, including hereditary diseases, cancer, and infectious diseases, which can inform the development of targeted therapies [5]. The ability to conduct drug screening and toxicity assessments using patient-derived organoids allows for a more personalized approach to treatment, as these organoids can reflect the unique genetic and phenotypic characteristics of the individual [14].

Despite the promising potential of organoids in transplantation and regenerative medicine, there are still challenges that need to be addressed. Issues related to large-scale production, control of heterogeneity, and clinical translation remain prevalent [42]. Continued research and interdisciplinary innovation are essential to fully harness the capabilities of organoids and facilitate their integration into clinical practice [1].

In summary, organoids represent a transformative approach in the field of regenerative medicine, particularly in the context of organoid transplants. Their capacity for personalization, coupled with advancements in engineering and bioengineering, positions them as a viable solution for addressing various therapeutic challenges in tissue repair and regeneration.

6 Challenges and Future Directions ​

6.1 Technical Limitations ​

Organoids have emerged as pivotal tools in biomedical research, with a diverse range of applications that span disease modeling, drug discovery, precision medicine, and regenerative medicine. These three-dimensional (3D) structures, derived from stem cells or primary tissues, mimic the architecture and function of human organs, thus providing valuable insights into various biological processes and disease mechanisms.

One of the primary applications of organoids is in disease modeling. They allow researchers to study the pathophysiology of various diseases, including hereditary diseases, infectious diseases, metabolic disorders, and cancers. Organoids can recapitulate the genetic and phenotypic characteristics of the tissue of origin, making them ideal for understanding disease mechanisms and progression in a controlled environment [5].

In drug discovery, organoids facilitate high-throughput screening of drug candidates, enabling assessments of drug toxicity and efficacy. Their ability to closely mimic human tissue responses enhances the reliability of preclinical drug testing compared to traditional two-dimensional cell cultures or animal models [2]. Furthermore, organoids have shown promise in precision medicine, where they can be used to develop patient-specific therapeutic strategies, thereby personalizing treatment plans based on individual genetic profiles [1].

Regenerative medicine is another significant application area for organoids. They have the potential to be utilized in tissue replacement and repair, addressing organ damage and functional abnormalities. Recent advancements in bioengineering have aimed to enhance the capabilities of organoids, enabling them to better mimic the complexities of human tissues and improve their viability for transplantation [45].

Despite the promising applications, the translational potential of organoids faces several challenges. One major technical limitation is the lack of standardized protocols for organoid culture, which can lead to variability in organoid size, structure, and functionality. This variability complicates the reproducibility of experiments and hinders the clinical applicability of organoid-derived insights [46].

Additionally, many current organoid systems rely on biologically-derived materials, such as Matrigel, which can introduce variability and may not be suitable for clinical applications due to safety concerns. The engineering of alternative biomaterials that provide more consistent and biocompatible environments for organoid growth is a critical area of ongoing research [7].

Moreover, challenges related to vascularization and immune integration of organoids remain significant barriers to their use in regenerative therapies. These aspects are crucial for the survival and function of transplanted organoids within the human body [45].

Future directions in organoid research include the integration of advanced technologies such as microfluidics, bioprinting, and artificial intelligence to enhance organoid functionality, scalability, and microenvironment control [1]. Additionally, efforts to develop engineered organoids that better mimic the physiological conditions of human tissues will be essential for overcoming existing limitations and advancing their clinical applications [47].

In conclusion, while organoids present transformative potential across various biomedical fields, addressing the technical limitations and challenges associated with their development and application will be crucial for realizing their full promise in research and clinical settings.

6.2 Ethical Considerations ​

Organoids are miniature, three-dimensional structures derived from stem cells that closely mimic the architecture and functionality of human organs. Their applications span a wide range of fields in biomedicine and biotechnology, including disease modeling, drug discovery, precision medicine, and regenerative medicine.

In disease modeling, organoids provide a powerful platform for studying the mechanisms of various diseases, including genetic disorders, infectious diseases, and cancer. They allow researchers to investigate disease progression in a controlled environment, which can lead to better understanding and potential therapeutic targets. For instance, organoids have been instrumental in elucidating genetic cell fate in hereditary diseases and malignancies, offering insights into disease mechanisms that may not be observable in traditional two-dimensional cell cultures or animal models [5].

In drug discovery, organoids facilitate high-throughput screening of drug efficacy and toxicity, providing a more physiologically relevant context than conventional models. The integration of organoid technology with advanced methodologies such as artificial intelligence and microfluidics has enhanced the ability to conduct rapid and cost-effective assessments of drug candidates [1]. This capability is crucial for precision medicine, where treatments can be tailored to the individual patient’s specific disease profile [2].

Furthermore, organoids hold significant promise in regenerative medicine, where they can be used for tissue engineering and potentially for organ transplantation. Their ability to replicate human tissue architecture makes them suitable candidates for developing replacement tissues [3]. The advancements in bioengineering have further expanded the potential applications of organoids, allowing for the creation of more complex tissue structures that can be used in clinical settings [13].

Despite these promising applications, organoid technology also faces numerous challenges. One major hurdle is the complexity of organoid cultures, which can vary significantly in their structure and function. Standardization and scalability of organoid production remain significant obstacles to their widespread clinical application [47]. Additionally, issues related to vascularization and immune integration are critical for the successful implementation of organoids in therapeutic contexts [1].

Ethically, the use of organoids raises several complex issues. These include concerns about the source of stem cells used to create organoids, informed consent from cell donors, and the moral status of organoids themselves. The potential for organoids to acquire human-like characteristics or capabilities through gene editing or other modifications further complicates the ethical landscape [48]. There is a pressing need for clear ethical guidelines and regulatory frameworks to govern organoid research and applications, ensuring that the benefits of this technology are realized without compromising ethical standards [49].

In conclusion, while organoids present transformative opportunities in various biomedical fields, their successful application is contingent upon addressing the challenges of standardization, ethical considerations, and the need for interdisciplinary collaboration to harness their full potential.

7 Conclusion ​

Organoids represent a groundbreaking advancement in biomedical research, with significant implications for disease modeling, drug discovery, regenerative medicine, and personalized therapy. Their ability to replicate human organ architecture and function provides researchers with powerful tools to study complex biological processes and disease mechanisms. The major findings highlight the versatility of organoids in cancer research, genetic disorders, and infectious diseases, where they have been shown to enhance our understanding of pathophysiology and therapeutic responses. Furthermore, the integration of organoids in high-throughput screening and personalized medicine approaches underscores their potential to transform clinical practice by facilitating tailored treatment strategies. However, challenges remain, including technical limitations related to standardization, scalability, and ethical considerations surrounding their use. Future research should focus on overcoming these hurdles through interdisciplinary collaboration, innovation in engineering techniques, and the establishment of clear ethical guidelines. As organoid technology continues to evolve, it holds the promise of significantly improving patient care and advancing our understanding of human biology.

References ​

  • [1] Ting Huang;Weitao Huang;Qiong Bian. Organoids as predictive platforms: advancing disease modeling, therapeutic innovation, and drug delivery systems.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2025. PMID:40939865. DOI: 10.1016/j.jconrel.2025.114222.
  • [2] Natan Roberto de Barros;Canran Wang;Surjendu Maity;Arne Peirsman;Rohollah Nasiri;Anna Herland;Menekse Ermis;Satoru Kawakita;Bruna Gregatti Carvalho;Negar Hosseinzadeh Kouchehbaghi;Rondinelli Donizetti Herculano;Zuzana Tirpáková;Seyed Mohammad Hossein Dabiri;Jean Lucas Tanaka;Natashya Falcone;Auveen Choroomi;RunRun Chen;Shuyi Huang;Elisheva Zisblatt;Yixuan Huang;Ahmad Rashad;Danial Khorsandi;Ankit Gangrade;Leon Voskanian;Yangzhi Zhu;Bingbing Li;Mohsen Akbari;Junmin Lee;Mehmet Remzi Dokmeci;Han-Jun Kim;Ali Khademhosseini. Engineered organoids for biomedical applications.. Advanced drug delivery reviews(IF=17.6). 2023. PMID:37967768. DOI: 10.1016/j.addr.2023.115142.
  • [3] Zhangcheng Zhu;Yiwen Cheng;Xia Liu;Wenwen Ding;Jiaming Liu;Zongxin Ling;Lingbin Wu. Advances in the Development and Application of Human Organoids: Techniques, Applications, and Future Perspectives.. Cell transplantation(IF=3.2). 2025. PMID:39874083. DOI: 10.1177/09636897241303271.
  • [4] Chunhui Cai;Xinxin Han. Organoids in biomedicine: Bridging innovation, disease modeling, and regulatory transformation.. Cell transplantation(IF=3.2). 2025. PMID:41126771. DOI: 10.1177/09636897251376507.
  • [5] Qigu Yao;Sheng Cheng;Qiaoling Pan;Jiong Yu;Guoqiang Cao;Lanjuan Li;Hongcui Cao. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.. MedComm(IF=10.7). 2024. PMID:39309690. DOI: 10.1002/mco2.735.
  • [6] Zeyu Wang;Shasha Zhao;Xiaolin Lin;Guanglong Chen;Jiawei Kang;Zhongping Ma;Yiming Wang;Zhi Li;Xiuying Xiao;Aina He;Dongxi Xiang. Application of Organoids in Carcinogenesis Modeling and Tumor Vaccination.. Frontiers in oncology(IF=3.3). 2022. PMID:35371988. DOI: 10.3389/fonc.2022.855996.
  • [7] Yue Huang;Xiaoyu Zhang;Wanjun Zhang;Jinglong Tang;Jing Liu. Rational design matrix materials for organoid development and application in biomedicine.. Regenerative biomaterials(IF=8.1). 2025. PMID:40556786. DOI: 10.1093/rb/rbaf038.
  • [8] Ancuta Jurj;Sergiu Pasca;Cornelia Braicu;Ioana Rusu;Schuyler S Korban;Ioana Berindan-Neagoe. Focus on organoids: cooperation and interconnection with extracellular vesicles - Is this the future of in vitro modeling?. Seminars in cancer biology(IF=15.7). 2022. PMID:34896267. DOI: 10.1016/j.semcancer.2021.12.002.
  • [9] Peter V Hauser. Advances in Organoid Research and Developmental Engineering.. Bioengineering (Basel, Switzerland)(IF=3.7). 2024. PMID:39768093. DOI: 10.3390/bioengineering11121275.
  • [10] T Thangam;Krupakar Parthasarathy;K Supraja;V Haribalaji;Vignesh Sounderrajan;Sudhanarayani S Rao;Sakthivel Jayaraj. Lung Organoids: Systematic Review of Recent Advancements and its Future Perspectives.. Tissue engineering and regenerative medicine(IF=4.1). 2024. PMID:38466362. DOI: 10.1007/s13770-024-00628-2.
  • [11] Sathidpak Nantasanti;Alain de Bruin;Jan Rothuizen;Louis C Penning;Baukje A Schotanus. Concise Review: Organoids Are a Powerful Tool for the Study of Liver Disease and Personalized Treatment Design in Humans and Animals.. Stem cells translational medicine(IF=4.9). 2016. PMID:26798060. DOI: 10.5966/sctm.2015-0152.
  • [12] Giuliana Rossi;Andrea Manfrin;Matthias P Lutolf. Progress and potential in organoid research.. Nature reviews. Genetics(IF=52.0). 2018. PMID:30228295. DOI: 10.1038/s41576-018-0051-9.
  • [13] Hairong Jin;Zengqi Xue;Jinnv Liu;Binbin Ma;Jianfeng Yang;Lanjie Lei. Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction.. Biomaterials research(IF=9.6). 2024. PMID:38628309. DOI: 10.34133/bmr.0016.
  • [14] Yaqi Li;Peiyuan Tang;Sanjun Cai;Junjie Peng;Guoqiang Hua. Organoid based personalized medicine: from bench to bedside.. Cell regeneration (London, England)(IF=4.7). 2020. PMID:33135109. DOI: 10.1186/s13619-020-00059-z.
  • [15] Kai Kretzschmar. Cancer research using organoid technology.. Journal of molecular medicine (Berlin, Germany)(IF=4.2). 2021. PMID:33057820. DOI: 10.1007/s00109-020-01990-z.
  • [16] Srushti Tambe;Rohit Kumar;Purnima Amin;Monalisa Mishra;Madhu Gupta;Kavitha Govarthanan;Ashwin Kumar Narasimhan;Piyush Kumar Gupta. Current aspects of organoid technology for biomaterial toxicity analysis.. Future medicinal chemistry(IF=3.4). 2023. PMID:37140141. DOI: 10.4155/fmc-2023-0043.
  • [17] Yusheng Lin;Li Jiang;Qiaojun He;Meng Yuan;Ji Cao. Progress and perspective of organoid technology in cancer-related translational medicine.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2022. PMID:35358798. DOI: 10.1016/j.biopha.2022.112869.
  • [18] Jillian R Love;Wouter R Karthaus. Next-Generation Modeling of Cancer Using Organoids.. Cold Spring Harbor perspectives in medicine(IF=10.1). 2024. PMID:37734867. DOI: 10.1101/cshperspect.a041380.
  • [19] Yuxuan Xiao;Yutao Li;Xilin Jing;Lin Weng;Xu Liu;Qingyun Liu;Kezhong Chen. Organoid models in oncology: advancing precision cancer therapy and vaccine development.. Cancer biology & medicine(IF=8.4). 2025. PMID:40708272. DOI: .
  • [20] Yuanhang Zhu;Nanshan Lin;Juan Li;Haoqian Zhang;Ping Zhang;Xin Cheng;Qian Yang;Ling Liu. Organoids in Genetic Disorders: from Disease Modeling to Translational Applications.. Stem cell reviews and reports(IF=4.2). 2025. PMID:40931310. DOI: 10.1007/s12015-025-10973-x.
  • [21] Pratibha Banerjee;Sabyasachi Senapati. Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases.. Stem cell reviews and reports(IF=4.2). 2024. PMID:38758462. DOI: 10.1007/s12015-024-10733-3.
  • [22] Devanjali Dutta;Inha Heo;Hans Clevers. Disease Modeling in Stem Cell-Derived 3D Organoid Systems.. Trends in molecular medicine(IF=13.8). 2017. PMID:28341301. DOI: 10.1016/j.molmed.2017.02.007.
  • [23] Yijing Wang;Dingkun Peng;Meilin Li;Meng Yao;Tianlong Li;Su Li;Hua-Ji Qiu;Lian-Feng Li. Organoids: physiologically relevant ex vivo models for viral disease research.. Journal of virology(IF=3.8). 2025. PMID:40879383. DOI: 10.1128/jvi.01132-25.
  • [24] Ji-O Ryu;Yu-Jeong Seong;Eunyoung Lee;Sang-Yun Lee;Dong Woo Lee. Applications and research trends in organoid based infectious disease models.. Scientific reports(IF=3.9). 2025. PMID:40645979. DOI: 10.1038/s41598-025-07816-7.
  • [25] Sijing Zhu;Dan Chen;Xinzhi Yang;Liuliu Yang;Yuling Han. Organoid Models to Study Human Infectious Diseases.. Cell proliferation(IF=5.6). 2025. PMID:39973397. DOI: 10.1111/cpr.70004.
  • [26] Lucas Felipe de Oliveira;Daniel Mendes Filho;Bruno Lemes Marques;Giovana Figueiredo Maciel;Ricardo Cambraia Parreira;José Rodrigues do Carmo Neto;Priscilla Elias Ferreira Da Silva;Rhanoica Oliveira Guerra;Marcos Vinicius da Silva;Helton da Costa Santiago;Alexander Birbrair;Alexandre H Kihara;Valdo José Dias da Silva;Talita Glaser;Rodrigo R Resende;Henning Ulrich. Organoids as a novel tool in modelling infectious diseases.. Seminars in cell & developmental biology(IF=6.0). 2023. PMID:36182613. DOI: 10.1016/j.semcdb.2022.09.003.
  • [27] Loïc Meudec;Negaar Goudarzi;Xavier Mariette;Gaetane Nocturne. Lessons from organoid engineering for rheumatic disease.. Joint bone spine(IF=4.3). 2025. PMID:40706747. DOI: 10.1016/j.jbspin.2025.105948.
  • [28] Jin Yan;Jean Monlong;Céline Cougoule;Sonia Lacroix-Lamandé;Agnès Wiedemann. Mapping the scientific output of organoids for animal and human modeling infectious diseases: a bibliometric assessment.. Veterinary research(IF=3.5). 2024. PMID:38926765. DOI: 10.1186/s13567-024-01333-7.
  • [29] Jun Li;Wendong Yang;Xiaoli Liu;Keda Yang;Jialin Zhou;Xiaochun Yang. Research progress of lung organoids in infectious respiratory diseases.. European journal of pharmacology(IF=4.7). 2025. PMID:41016568. DOI: 10.1016/j.ejphar.2025.178201.
  • [30] Daisong Wang;Remi Villenave;Nadine Stokar-Regenscheit;Hans Clevers. Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges.. Nature reviews. Drug discovery(IF=101.8). 2025. PMID:41225057. DOI: 10.1038/s41573-025-01317-y.
  • [31] Stefan M Czerniecki;Nelly M Cruz;Jennifer L Harder;Rajasree Menon;James Annis;Edgar A Otto;Ramila E Gulieva;Laura V Islas;Yong Kyun Kim;Linh M Tran;Timothy J Martins;Jeffrey W Pippin;Hongxia Fu;Matthias Kretzler;Stuart J Shankland;Jonathan Himmelfarb;Randall T Moon;Neal Paragas;Benjamin S Freedman. High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping.. Cell stem cell(IF=20.4). 2018. PMID:29779890. DOI: 10.1016/j.stem.2018.04.022.
  • [32] Jakob J Metzger;Carlota Pereda;Arjun Adhikari;Tomomi Haremaki;Szilvia Galgoczi;Eric D Siggia;Ali H Brivanlou;Fred Etoc. Deep-learning analysis of micropattern-based organoids enables high-throughput drug screening of Huntington's disease models.. Cell reports methods(IF=4.5). 2022. PMID:36160045. DOI: 10.1016/j.crmeth.2022.100297.
  • [33] Rui Zhao;Qiushi Feng;Yangyang Xia;Lingzi Liao;Shang Xie. Iteration of Tumor Organoids in Drug Development: Simplification and Integration.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2025. PMID:41155654. DOI: 10.3390/ph18101540.
  • [34] Lisa Liu;Lei Yu;Zhichao Li;Wujiao Li;WeiRen Huang. Patient-derived organoid (PDO) platforms to facilitate clinical decision making.. Journal of translational medicine(IF=7.5). 2021. PMID:33478472. DOI: 10.1186/s12967-020-02677-2.
  • [35] Yunyuan Shao;Juncheng Wang;Anqi Jin;Shicui Jiang;Lanjie Lei;Liangle Liu. Biomaterial-assisted organoid technology for disease modeling and drug screening.. Materials today. Bio(IF=10.2). 2025. PMID:39866785. DOI: 10.1016/j.mtbio.2024.101438.
  • [36] Dilpreet Singh;Akshay Thakur; Rakesh;Akshay Kumar. Advancements in Organoid-Based Drug Discovery: Revolutionizing Precision Medicine and Pharmacology.. Drug development research(IF=4.2). 2025. PMID:40522262. DOI: 10.1002/ddr.70121.
  • [37] Junfa Yang;Yipin Yang;Pengkai Xu;Yong Yao;Heng Tian;Xinyi Wang;Hui Fang;Shangqing Ge;Yan Yao;Yafen Wang;Lin Hu;Bangjie Chen;Tao Xu. Organoid technologies in antitumor drug screening: past development, present applications, and future prospects.. International journal of surgery (London, England)(IF=10.1). 2025. PMID:40402643. DOI: 10.1097/JS9.0000000000002530.
  • [38] Hui Yang;Yinuo Wang;Peng Wang;Ning Zhang;Pengyuan Wang. Tumor organoids for cancer research and personalized medicine.. Cancer biology & medicine(IF=8.4). 2021. PMID:34520134. DOI: .
  • [39] Yunqi Man;Yanfei Liu;Qiwen Chen;Zhirou Zhang;Mingfeng Li;Lishang Xu;Yifu Tan;Zhenbao Liu. Organoids-On-a-Chip for Personalized Precision Medicine.. Advanced healthcare materials(IF=9.6). 2024. PMID:39397335. DOI: 10.1002/adhm.202401843.
  • [40] Saade Abdalkareem Jasim;Dmitry Olegovich Bokov;Wanich Suksatan;Fahad Alsaikhan;Mohammed Abed Jawad;Satish Kumar Sharma;Supat Chupradit;Lakshmi Thangavelu. Organoid Models of Heart Diseases: Find a New Channel in Improvements of Cardiac Regenerative Medicine.. Current medicinal chemistry(IF=3.5). 2023. PMID:36281859. DOI: 10.2174/0929867330666221021122603.
  • [41] Nidhi Jalan-Sakrikar;Teresa Brevini;Robert C Huebert;Fotios Sampaziotis. Organoids and regenerative hepatology.. Hepatology (Baltimore, Md.)(IF=15.8). 2023. PMID:35596930. DOI: 10.1002/hep.32583.
  • [42] Biao Yu;Dongyang Zhou;Fuxiao Wang;Xiao Chen;Mengmeng Li;Jiacan Su. Organoids for tissue repair and regeneration.. Materials today. Bio(IF=10.2). 2025. PMID:40621183. DOI: 10.1016/j.mtbio.2025.102013.
  • [43] Naihsin Hsiung;Yikun Ju;Kai Yang;Pu Yang;Weiliang Zeng;Hongli Zhao;Pei Zou;Jiandong Ye;Kemin Yi;Xiancheng Wang. Organoid-based tissue engineering for advanced tissue repair and reconstruction.. Materials today. Bio(IF=10.2). 2025. PMID:40727081. DOI: 10.1016/j.mtbio.2025.102093.
  • [44] Yinghua Wu;Wenrui Ye;Yong Gao;Zhenjie Yi;Zhuohui Chen;Chunrun Qu;Jing Huang;Fangkun Liu;Zhixiong Liu. Application of Organoids in Regenerative Medicine.. Stem cells (Dayton, Ohio)(IF=3.6). 2023. PMID:37724396. DOI: 10.1093/stmcls/sxad072.
  • [45] Sewon Park;Seung-Woo Cho. Bioengineering toolkits for potentiating organoid therapeutics.. Advanced drug delivery reviews(IF=17.6). 2024. PMID:38447933. DOI: 10.1016/j.addr.2024.115238.
  • [46] Xulong Fan;Kun Hou;Gaojian Liu;Ruolin Shi;Wenjie Wang;Gaofeng Liang. Strategies to overcome the limitations of current organoid technology - engineered organoids.. Journal of tissue engineering(IF=7.0). 2025. PMID:40290859. DOI: 10.1177/20417314251319475.
  • [47] Monique M A Verstegen;Rob P Coppes;Anne Beghin;Paolo De Coppi;Mattia F M Gerli;Nienke de Graeff;Qiuwei Pan;Yoshimasa Saito;Shaojun Shi;Amir A Zadpoor;Luc J W van der Laan. Clinical applications of human organoids.. Nature medicine(IF=50.0). 2025. PMID:39901045. DOI: 10.1038/s41591-024-03489-3.
  • [48] Vasiliki Mollaki. Ethical Challenges in Organoid Use.. Biotech (Basel (Switzerland))(IF=3.1). 2021. PMID:35822766. DOI: 10.3390/biotech10030012.
  • [49] Annelien L Bredenoord;Hans Clevers;Juergen A Knoblich. Human tissues in a dish: The research and ethical implications of organoid technology.. Science (New York, N.Y.)(IF=45.8). 2017. PMID:28104841. DOI: 10.1126/science.aaf9414.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Organoids · Biomedical Research · Personalized Medicine · Cancer Research · Regenerative Medicine

© 2025 MaltSci